| Methods |
4‐ to 5‐week single‐blind placebo run‐in during which previous antihypertensive medication withdrawn; patients qualified for 3‐ to 4‐week enalapril challenge period if sitting DBP 95‐114 mm Hg and difference between their average sitting DBP values for last 2 visits of placebo run‐in period did not exceed 12 mm Hg; during enalapril challenge patients received enalapril 20 mg daily (10 mg for first 3 days); patients who developed persistent, nonproductive cough while receiving enalapril were then given placebo for 2‐ to 4‐weeks to allow cough to clear; eligible patients (those meeting inclusion criteria for enalapril challenge and whose cough subsequently cleared during placebo washout period) then entered 6‐week double‐blind treatment |
| Participants |
Eprosartan: n=46(27 males,19 females); baseline sitting SBP=153.1(14.9) mm Hg, DBP=101.5(4.1) mm Hg, HR=75.9(7.5) bpm;
Placebo:n=45(21 males,24 females); baseline sitting SBP=154.1(14.1) mm Hg, DBP=99.8(4.0) mm Hg, HR=74.4(8.1) bpm |
| Interventions |
Eprosartan 300 mg twice daily (200 mg for first 3 days);
Placebo |
| Outcomes |
Mean change from baseline in sitting DBP;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported, DBP data from text, p. 8 and Figure 3, p. 10; time of BP measurement not reported; BP measurement device not reported; Jadad Score=4; funding source= SmithKline Beecham Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
